08/11/2025
🌟 ISAD2025: Day 2 Highlights
🔹We opened with “The Body Talks” symposium, featuring impactful talks from Dr Calum Moulton, Dr Toby Pillinger, and Prof Valeria Mondelli, exploring the important bidirectional links between mood disorders and gut and cardiometabolic health — and how these should guide treatment choices to maximise benefit and minimise harm.
🔹 The “Lithium: old drug, new tricks” session, offered fresh perspectives on why and how we should be maximising the use of this gold-standard mood stabiliser, with insights from state-of-the-art neuroimaging and novel research on the benefits of low dose Lithium, delivered by Dr David Cousins and Dr Rebecca Strawbridge. Then, Scott Murray from Aurovian presented a novel approach to measuring lithium levels, followed by a panel discussion on the opportunities and challenges of its’ implementation, with the invaluable patient perspective provided by Dr Clare Dolman.
🔹 We then welcomed Prof Cathryn Lewis for a thought-provoking keynote on the role of genetics in depression, highlighting the missed opportunities coming from underusing genetic testing in antidepressant treatment trials.
🔹 Over lunch, we enjoyed a fantastic poster session showcasing emerging research from across the affective disorders field.
🔹 The afternoon featured a joint symposium with the Swedish Psychiatric Association, co-chaired by Prof Fiona Gaughran and Ass. Prof. Jonas Eberhard, The talks from Ass. Prof. Steinn Steingrimsson, Ass. Prof. Matilda Naesström, and Ass. Prof. Jonas Eberhard on the Swedish experience of embedding research and training into clinical practice, sparked a lively debate on the future of AI in psychiatric training and practice.
🔹 Continuing the AI theme, Prof Melvin McInnis delivered the final keynote on how AI-based phenotype clustering could address long-standing challenges in psychiatric classification and pave the way for precision psychiatry.
🔹 The Meeting concluded with the “Altered Horizons” symposium, where Dr James Rucker and Dr David Erritzoe provided a big picture perspective on the promise and challenges of psychedelic therapies, followed by Dr Luke Jelen’s fascinating work on the role of the opioid system in ketamine’s acute antidepressant effects.
A big thank you to all our speakers, chairs, and attendees for making this another inspiring day of scientific discussion!